Title: Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell
Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-
Label, Multicenter Phase 1b Study
Version: 0 Date: 24 Jul 2021
Reviewer's report:
With few treatment options for unresectable, advanced ESCCs, this study appears to be very
useful. This report is intriguing and will meet the criteria of this journal. However, there are
some points that should be addressed.
1. What was the patient's weight or body surface area? I think that the dose of anti-EGFR
antibody is usually determined per body weight or body surface area. Should be specified.
Title: Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell
Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-
Label, Multicenter Phase 1b Study
Version: 0 Date: 24 Jul 2021
Reviewer's report:
With few treatment options for unresectable, advanced ESCCs, this study appears to be very
useful. This report is intriguing and will meet the criteria of this journal. However, there are
some points that should be addressed.
1. What was the patient's weight or body surface area? I think that the dose of anti-EGFR
antibody is usually determined per body weight or body surface area. Should be specified.
Please review this paper.
user
Title: Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell
Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-
Label, Multicenter Phase 1b Study
Version: 0 Date: 24 Jul 2021
Reviewer's report:
With few treatment options for unresectable, advanced ESCCs, this study appears to be very
useful. This report is intriguing and will meet the criteria of this journal. However, there are
some points that should be addressed.
1. What was the patient's weight or body surface area? I think that the dose of anti-EGFR
antibody is usually determined per body weight or body surface area. Should be specified.
assistant